FIG 2.

Response to larotrectinib. A 46-year-old man diagnosed with stage IV (T4N0M1) non–small-cell lung cancer previously progressed on first-line platinum-based chemotherapy (after 9 months) and on the PD-1 inhibitor dostarlimab (after 2 months). A TPM3-NTRK1 fusion was identified on molecular profiling, and larotrectinib was initiated on trial. A brisk partial response was achieved at 1.8 months, which was subsequently confirmed; the patient discontinued treatment because of progressive disease after a durable 39 months of disease control. NTRK, neurotrophic tyrosine receptor kinase; PD-1, programmed cell death-1.